Sweet syndrome following Moderna COVID-19 vaccine: A case report

Frederic Pelchat, Cynthia Fournier, Emilie Perron, Martin Gilbert and Bernard Delisle

Abstract
With the COVID-19 pandemic, vaccines have been administered all around the world probably more than ever. Even though they are considered safe, with such a huge quantity of doses used, many adverse effects including cutaneous ones were reported. We report here the case of a male adult with a history of monoclonal gammopathy of undetermined significance who presented with an extensive cutaneous eruption of indurated erythematous papules and plaques 2 days after receiving his first dose of Moderna COVID-19 vaccine (mRNA-1273 SARS-CoV-2 vaccine). Histopathology was compatible with a histiocytoid Sweet syndrome and history suggested that the vaccine contributed to the eruption.

Keywords
Sweet syndrome, COVID-19 vaccine, Moderna vaccine, COVID vaccine

Introduction
Sweet syndrome, also called acute febrile neutrophilic dermatosis, is an uncommon inflammatory disease. Characteristic cutaneous lesions consist of edematous, erythematous, and tender papules and plaques that can occur on any part of the body but favor the head, neck, and upper extremities. Skin manifestations are often accompanied by systemic symptoms like fever, malaise, myalgias, and arthralgias. Leukocytosis with neutrophilia and elevated inflammatory markers are frequent laboratory findings. Usually, a Sweet syndrome diagnostic imposes a medical workup, and in at least half of the patients, a trigger or an associated disorder can be found. Malignancies, infections, drugs, autoimmune, and gastrointestinal disorders are the most common associations. Cases of Sweet syndrome have been reported following some vaccinations such as influenza and pneumococcal.

COVID-19 pandemic made it necessary and urgent for pharmaceutical companies to develop and make accessible vaccines to help control the disease spreading on the planet. Vaccines have been and will continue to be used extensively. Thereby, adverse reactions have been reported including a variety of cutaneous ones. According to current literature, a few cases of Sweet syndrome following a COVID-19 vaccine have been described and we report one of the first histiocytoid variants of Sweet syndrome triggered by this vaccine.

Case report
A 60-year-old male with a history of a traumatic skin burn on his back, a monoclonal gammopathy of undetermined significance and one episode of Sweet syndrome following upper respiratory tract infection presented to the emergency with a skin eruption with abrupt onset. He presented multiple, tender, indurated erythematous papules and plaques over his face, trunk, upper, and lower limbs (Figures 1–4). The eruption started 2 days after receiving his first dose of Moderna COVID-19 vaccine (mRNA-1273 SARS-CoV-2 vaccine) by intramuscular injection. Interestingly, a year before, he had the same eruption following an upper respiratory tract infection. He was seen by a dermatologist who performed a skin biopsy and histopathology was consistent with a diagnosis of classic Sweet syndrome. At this moment, he did not have a COVID-19 screening test. A large workup was made at the time of this first episode of Sweet syndrome and
permitted to identify a monoclonal gammopathy of undetermined significance.

There were no other systemic signs or symptoms including fever, chills, arthralgias, or myalgias. He only complained of mild malaise and fatigue. Laboratory tests revealed a mild neutrophilia at $8310 \times 10^9/L$ (normal range $1900–7000 \times 10^9/L$) and an elevated sedimentation rate at 15 mm/h (normal range 0–10). His SARS-CoV-2 blood serology was negative. Histopathology revealed superficial and mid-dermal histiocytoid cells infiltrate with a few accompanying T lymphocytes (Figures 5 and 6). Histiocytoid cells were CD68+, CD163+, and myeloperoxidase+ (Figures 7 and 8). Skin direct immunofluorescence studies did not reveal any immunoglobulin deposit. Histopathology was compatible with histiocytoid Sweet syndrome variant.

We treated the patient with systemic corticosteroid and he had an excellent response. We continued prednisone for a few months in tapering doses since the eruption tended to recur at many attempts of stopping prednisone. The eruption gradually subsided after. Based on the patient’s history, his COVID-19 vaccine trigger, physical examination, histopathology, laboratory findings, and excellent response to systemic corticosteroid, the patient met the diagnosis criteria of Sweet syndrome following COVID-19 Moderna vaccination.

Twelve weeks after his first dose of COVID-19 vaccine, he received his second dose of the same Moderna COVID-19
vaccine. Less than 24 h later, he developed the same acute eruption of tender erythematous papules and plaques that rapidly subsided 48 h after. The patient was still on a low dose of corticosteroid. A few weeks later, he received his third dose of the same Moderna COVID-19 vaccine. He was still on a low dose of corticosteroid. He did not experience any cutaneous eruption at this time, not even when the corticosteroid was fully weaned off.

Discussion

According to the manufacturer, Moderna COVID-19 Vaccine contains a lipid nanoparticle comprised of a messenger ribonucleic acid (mRNA) encoding the pre-fusion stabilized Spike glycoprotein of SARS-CoV-2 virus. It is indicated for active immunization against coronavirus disease 2019.

Extensive data about the COVID-19 different types of vaccines and their side effects are still to be made. Many cases of cutaneous adverse effects following vaccination have been described. They include local cutaneous reactions, urticaria, morbilliform eruptions, immune dermatoses, and other rare reactions.

We presented the case of a Sweet syndrome following COVID-19 vaccination. Our patient therefore met the criteria for the diagnosis of Sweet syndrome. The short time interval between the administration of the vaccine and the cutaneous eruption allows us to identify the vaccine as the principal trigger. Sweet syndrome has been described following pneumococcal, influenza, and BCG (Bacille Calmette–Guérin) vaccination. To our knowledge, only a few cases of Sweet syndrome following COVID-19 vaccination have

Figure 5. Skin biopsy show superficial and mid dermal histiocytoid cells infiltrate with a few accompanying T lymphocytes (low power view, hematoxylin and eosin stain).

Figure 6. High power view of histiocytoid cells infiltrate in the dermis on hematoxylin and eosin stain.

Figure 7. CD68 antibody staining of histiocytoid cells.

Figure 8. Myeloperoxidase (MPO) antibody staining of histiocytoid cells.
been reported to date. Four of them were associated with the Oxford-AstraZeneca vaccine.\textsuperscript{12–15} Two others with the mRNA Pfizer-BioNTech vaccine\textsuperscript{16,17} and only one\textsuperscript{18} with the same vaccine as our case, the Moderna mRNA01273 vaccine. The patient in this last case had a neutrophilic dermatosis with histiocytoid cells on histopathology and he also presented extra-cutaneous adverse effects attributed to the vaccine such as myoclonus and encephalitis. Vaccination seems to trigger an immune response and activate or reactivate this syndrome. Our case is one of the first reported histiocytoid variant of Sweet syndrome following a COVID-19 vaccine. Histiocytoid variant is an uncommon variant of Sweet syndrome. It is more often associated to malignancies than other variants of the disease.\textsuperscript{19} Our patient was known to the research, authorship, and/or publication of this article.

### Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

### Informed consent
Written informed consent for patient information and images to be published was provided by the patient.

### ORCID iDs
Frederic Pelchat  https://orcid.org/0000-0001-7961-2891
Cynthia Fournier  https://orcid.org/0000-0003-3806-1098
Emilie Perron  https://orcid.org/0000-0002-7033-8053

### References
1. Moschella SL and Davis M. Neutrophilic dermatoses. In: Bologna JL, Schaffer JV and Cerroni L (eds) Dermatology. Amsterdam: Elsevier, 2018, p. 453.
2. Pedrosa AF, Morais P, Nogueira A, et al. Sweet’s syndrome triggered by pneumococcal vaccination. Cutan Ocul Toxicol 2013; 32(3): 260–261.
3. Maddox PR and Motley RJ. Sweet’s syndrome: a severe complication of pneumococcal vaccination following emergency splenectomy. Br J Surg 1990; 77(7): 809–810.
4. Jovanović M, Poljacci M, Vujanović L, et al. Acute febrile neutrophilic dermatosis (Sweet’s syndrome) after influenza vaccination. J Am Acad Dermatol 2005; 52(2): 367–369.
5. Tan AW, Tan HH and Lim PL. Bullous Sweet’s syndrome following influenza vaccination in a HIV-infected patient. Int J Dermatol 2006; 45(10): 1254–1255.
6. Wolf R, Barziali A and Davidovici B. Neutrophilic dermatosis of the hands after influenza vaccination. Int J Dermatol 2009; 48(1): 66–68.
7. Hali F, Sbai M, Benchikhi H, et al. Syndrome de Sweet après vaccination antigrippale H1N1 [Sweet’s syndrome after H1N1 influenza vaccination]. Ann Dermatol Venereol 2010; 137(11): 740–741.
8. Carpentier O, Piette F and Delaporte E. Sweet’s syndrome after BCG vaccination. Acta Derm Venereol 2002; 82(3): 221.
9. Radell B and Harms M. Acute febrile neutrophilic dermatosis (Sweet’s syndrome) following BCG vaccination. Acta Derm Venereol. 1986; 66(4): 357–358.
10. Moderna. Product monograph—COVID-19 vaccine. https://www.modernacovid19global.com/ca/product-monograph.pdf
11. McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 2021; 85(1): 46–55.
12. Majid I and Mearaj S. Sweet syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly female. Dermatol Ther 2021; 34(6): e15146.
13. Sechi A, Pierobon E, Pezzolo E, et al. Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine. Clin Exp Dermatol 2022; 47(2): 437–440.
14. Žagar T, Hlača N, Brajac I, et al. Bullous Sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine. Br J Dermatol 2022; 186(3): e110.
15. Capassoni M, Ketabchi S, Cassisa A, et al. AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event: a case report. J Med Virol 2021; 93(10): 5718–5720.
16. Darrigade AS, Théophile H, Sanchez-Pena P, et al. Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine. Allergy 2021; 76(10): 3194–3196.
17. Baffa ME, Maglie R, Giovannozzi N, et al. Sweet syndrome following SARS-CoV2 Vaccine. Vaccines 2021; 9(11): 1212.
18. Torrealba-Acosta G, Martin JC, Huttenbach Y, et al. Acute encephalitis, myoclonus and Sweet syndrome after mRNA-1273 vaccine. BMJ Case Rep 2021; 14(7): e243173.
19. Haber R, Feghal J and El Gemayel M. Risk of malignancy in histiocytoid Sweet syndrome: a systematic review and reappraisal. J Am Acad Dermatol 2020; 83(2): 661–663.